immune-mediated dermatologic diseases treated with rituximab COVID-19 vaccine immunogenicity Rituximab vaccination COVID-19 vaccines immune-mediated dermatologic diseases
Conditions
Interventions
Immune-mediated dermatologic disease patient who received rituximab prior to COVID-19 vaccination,Immune-mediated dermatologic disease patient who have never received rituximab prior to COVID-19 vacci
Basic Science,Basic Science
Rituximab users,Non-rituximab users
Sponsors
Division of Dermatology, Department of Internal Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Being participants of our previous prospective cohort study or the one conducted parallel to ours by rheumatologists in the same institution, which evaluated immunogenicity of various types of COVID-19 vaccines in patients with immune-mediated dermatologic diseases (TCTR20220317008) 2. Subjects who received at least one course of rituximab using any protocols before vaccination were included as an exposed group. 3. Rituximab-naive subjects were recruited as an unexposed group. *exposed and unexposed group were matched for age and sex.
Exclusion criteria
Exclusion criteria: 1. Subjects received rituximab or were diagnosed with COVID-19 between the first dose vaccination to the vaccine's immunogenicity assessment date 2. The vaccine's immunogenicity data were missing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Humoral immune response 28 days post-vaccination Seroconversion rates (positive tests for SARS-CoV-2 IgG, SARS-CoV-2-specific surrogate viral neutralization or micro-neutralization assays) | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
Thailand
Contacts
Public ContactChutima Sereeaphinan
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Outcome results
None listed